Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation

Nieuwlaat, Robby; Olsson, S. Bertil; Lip, Gregory Y.H.; Camm, A. John; Breithardt, Günter; Capucci, Alessandro; Meeder, Joan G.; Prins, Martin H.; Lévy, Samuel; Crijns, Harry J.G.M.

doi:10.1016/j.ahj.2007.03.008

Cited by 197 publications

(165 citation statements)

References 18 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Zintegrowane, usystematyzowane podejście do leczenia AF, które z powodzeniem zastosowano w innych dziedzinach medycyny [322][323][324], ułatwi spójne, zgodne z wytycznymi postępowanie u wszystkich pacjentów [325] (ryc. 6), stwarzając szansę poprawy klinicznych wyników leczenia [42,326,327]. Takie podejścia są zgodne z propozycją Ramowego Programu Innowacyjnej Opieki w Chorobach Przewlekłych (Innovative Care for Chronic Conditions Framework) wysuniętą przez Światową Organizację Zdrowia [328].…”

Section: Zintegrowane Postępowanie U Pacjentów Z Migotaniem Przedsionkówunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,379

4,206

View full text Add to dashboard Cite

Section: Zintegrowane Postępowanie U Pacjentów Z Migotaniem Przedsionkówunclassified

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Kirchhof

Benussi

Kotecha³

et al. 2016

Kardiol Pol

2,379

4,206

View full text Add to dashboard Cite

“…In the Euro Heart Survey, only about 35% of patients remained on VKAs for 5 years. 26 Cruess and others 27 sought to explain the association between attitudinal and behavioural factors related to nonadherence to warfarin medication regimens. A number of treatment prognostic scales (Interventional Fragility, Medication Abuse, Information Discomfort, and Utilization Excess), as well as social isolation, were associated with warfarin nonadherence.…”

Section: Discussionmentioning

confidence: 99%

Management of Stroke Prevention in Canadian Patients with Atrial Fibrillation at Moderate to High Risk of Stroke

Semchuk

Levac

Lara³

et al. 2013

CJHP

View full text Add to dashboard Cite

show abstract

“…Furthermore, for patients with AF at high risk of stroke, underuse of antithrombotic therapy is associated with poorer outcomes. 30 Research has been conducted to attempt to determine why VKAs are often used suboptimally. There are a number of different reasons given by physicians for not prescribing VKAs.…”

Section: Discrepancies Between Clinical Trials Guidelines and Real-mentioning

confidence: 99%

Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants

Verheugt

2013

Clinical Cardiology

View full text Add to dashboard Cite

Patients with atrial fibrillation (AF) have an increased stroke risk compared with those in sinus rhythm, although the absolute risk for individual patients is modulated by the presence of various additional risk factors. Patient selection for oral anticoagulation for stroke prevention is based on risks of stroke and bleeding. Although CHADS 2 (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke or transient ischemic attack) is the most widely used scheme for evaluating stroke risk in patients with AF, several other stroke risk factors are not included; therefore, many patients' stroke risk may be underestimated, contributing to the underuse of anticoagulants. Furthermore, a substantial proportion of patients are categorized as being at moderate risk (CHADS 2 = 1), and there has been some ambiguity regarding optimum thromboprophylaxis in this group. -VASc = 0), who are unlikely to benefit from antithrombotic therapy. For all others, an oral anticoagulant may be the preferred approach, simplifying clinical decision making. Implementation of CHA 2 DS 2 -VASc may also result in an increased proportion of patients receiving anticoagulation. The emergence of newer oral anticoagulants that can be given without routine coagulation monitoring, with improved benefit-risk profiles vs vitamin K antagonists, promises to simplify therapy for patients with AF at risk of stroke. This, coupled with advances in stroke risk stratification, is expected to improve patient outcomes and reduce the burden of AF-related stroke. IntroductionAtrial fibrillation (AF) is the most frequent clinically relevant cardiac arrhythmia encountered in the outpatient clinic, 1 affecting ∼ 1% of the US population and up to 10% of individuals age ≥80 years, with a higher prevalence among men than among women at all ages. 2 It is predicted that the prevalence of AF will continue to rise in the coming decades. 3 Patients with AF are at an increased risk of cardioembolic stroke; their risk is approximately 5-fold greater than for patients in sinus rhythm, 4 although the absolute risk for individual patients is highly variable depending on the presence or absence of various risk factors. 5,6

show abstract

Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation

Cited by 197 publications

References 18 publications

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Management of Stroke Prevention in Canadian Patients with Atrial Fibrillation at Moderate to High Risk of Stroke

Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants

Contact Info

Product

Resources

About